Our Pricing

Understanding Wegovy Doses for Weight Loss: A Complete UK Guide

Wegovy doses weight loss treatment follows a carefully structured escalation schedule designed to optimise results whilst minimising side effects. As a UK-registered pharmacy, we've guided thousands of patients through the Wegovy dosing journey, from the initial 0.25mg starting dose through to the 2.4mg maintenance dose that delivers clinically proven weight loss outcomes.

How Wegovy Doses Weight Loss: The Science Behind Dose Escalation

Wegovy doses weight loss through semaglutide, a GLP-1 receptor agonist that mimics the body's natural incretin hormones. The medication works by slowing gastric emptying, reducing appetite, and modulating areas of the brain responsible for food intake regulation [1]. Clinical trials demonstrate that the therapeutic effect is dose-dependent, with higher doses correlating to greater average weight reduction.

The dose escalation protocol isn't arbitrary—it's designed to allow your body to adapt gradually to semaglutide's effects. Starting at 0.25mg weekly and increasing monthly helps minimise gastrointestinal side effects whilst building towards the therapeutic 2.4mg maintenance dose. In the landmark STEP trials, participants who reached and maintained the 2.4mg dose achieved an average weight loss of 15-17% of their initial body weight over 68 weeks [1].

Each Wegovy dose contains the same active ingredient—semaglutide—but in progressively higher concentrations. The pre-filled pens are colour-coded and clearly labelled to prevent dosing errors. Our clinical team ensures every patient understands their current dose and when to escalate, with regular check-ins throughout the treatment journey.

The Complete Wegovy Doses Weight Loss Schedule: Month by Month

The standard Wegovy doses weight loss schedule follows a five-month escalation pathway. Month 1 begins with 0.25mg once weekly—this initial dose allows your body to acclimatise to semaglutide whilst introducing the appetite-suppressing effects. Patients typically notice reduced hunger and smaller portion sizes even at this starter dose.

Month 2 increases to 0.5mg weekly, where many patients report more pronounced appetite control and early weight loss results. Month 3 advances to 1mg weekly, Month 4 to 1.7mg weekly, and finally Month 5 onwards maintains the therapeutic 2.4mg weekly dose [2]. This is where maximum weight loss efficacy occurs, supported by sustained GLP-1 receptor activation.

Some patients may need to remain at a lower dose for an additional month if they experience persistent nausea or other tolerability issues. Our prescribers assess individual response and can adjust the escalation timeline accordingly—there's no universal timeline that suits everyone, and clinical judgement always takes precedence over rigid protocols.

What Happens If You Miss a Wegovy Dose?

If you miss a Wegovy dose and it's been less than 5 days since your scheduled injection day, administer the missed dose as soon as you remember, then return to your regular weekly schedule. If more than 5 days have passed, skip the missed dose entirely and resume with your next scheduled dose [3]. Never double up doses to compensate—this significantly increases the risk of nausea, vomiting, and other adverse effects.

Wegovy Doses Weight Loss Results: What to Expect at Each Stage

Wegovy doses weight loss outcomes vary by individual, but clinical data provides clear benchmarks. During the escalation phase (Months 1-4), patients typically lose 5-8% of their starting weight as doses increase and appetite suppression strengthens [1]. This initial phase is critical for building sustainable habits around portion control and food choices.

Once the 2.4mg maintenance dose is reached, weight loss continues at a steady pace. By Month 6-9, average weight reduction reaches 10-12%, and by Month 12-16, many patients achieve 15-17% total body weight loss when combined with dietary modifications and increased physical activity [2]. These figures represent averages from the STEP trial programme—individual results depend on adherence, baseline BMI, metabolic factors, and lifestyle adjustments.

It's important to recognise that Wegovy doses weight loss as a gradual, sustained process rather than rapid shedding. Patients who maintain the 2.4mg dose alongside behavioural changes see the most durable outcomes. Our clinical team monitors progress through regular consultations, adjusting treatment plans when weight loss plateaus or side effects require dose modification.

Wegovy Doses Weight Loss Pricing: Transparent UK Costs at Cured Pharmacy

Wegovy doses weight loss treatment is available at Cured Pharmacy from £124.99 per pen, representing the cheapest UK price for genuine, MHRA-licensed semaglutide. Each pen contains a one-month supply at your current dose level, clearly labelled and colour-coded for safety. New patients receive £20 off their first order using code Weightlossnew, reducing the initial month to just £124.99.

Pricing remains consistent across all dose strengths—whether you're on the 0.25mg starter dose or the 2.4mg maintenance dose, the cost per pen stays the same. This transparent pricing model eliminates confusion and allows patients to budget accurately for their weight loss journey. All orders include free next-day delivery in discreet, unmarked packaging, with no hidden fees or consultation charges.

Every Wegovy prescription requires a free online clinical assessment completed by a UK-registered prescriber. The consultation takes under 3 minutes, and most patients receive approval within hours. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all dispensing to ensure every prescription meets MHRA safety standards and GPhC regulatory requirements.

Does Insurance or the NHS Cover Wegovy Doses?

NHS provision of Wegovy is currently limited to specialist weight management services in specific circumstances, typically requiring a BMI over 35 with comorbidities and prior evidence of diet/exercise attempts [4]. Most UK patients access Wegovy through private prescription. At £124.99 per pen from Cured Pharmacy, private treatment remains affordable compared to market alternatives, with no waiting lists or restrictive eligibility criteria beyond clinical suitability.

Managing Side Effects Across Different Wegovy Doses Weight Loss Stages

Wegovy doses weight loss treatment is generally well-tolerated, but side effects—predominantly gastrointestinal—are most common during dose escalation. Nausea affects approximately 44% of patients at some point during treatment, typically peaking 1-3 days post-injection and subsiding as the body adapts [3]. Starting at the low 0.25mg dose and escalating gradually significantly reduces the severity and duration of these effects.

Other common side effects include diarrhoea (30%), constipation (24%), vomiting (24%), and abdominal discomfort (20%) [3]. These are usually mild to moderate and diminish over time. Eating smaller, more frequent meals, avoiding high-fat foods immediately after injection, and staying well-hydrated can substantially improve tolerability. If side effects persist or worsen, our prescribers may recommend staying at your current dose for an additional month before escalating.

Serious side effects are rare but require immediate medical attention: severe persistent abdominal pain (possible pancreatitis), rapid heart rate, significant dehydration, or allergic reactions. Our clinical team provides clear guidance on warning signs and when to seek urgent care. Every patient receives a comprehensive information leaflet with their first prescription detailing side effect management strategies specific to their current Wegovy dose.

Wegovy Doses Weight Loss: Long-Term Maintenance and Treatment Duration

Wegovy doses weight loss as a long-term treatment rather than a short-term intervention. Once the 2.4mg maintenance dose is reached and target weight loss achieved, most patients continue weekly injections indefinitely to sustain results. Clinical data shows that discontinuing Wegovy typically results in gradual weight regain, with patients regaining approximately two-thirds of lost weight within one year of stopping [5].

This isn't a failure of willpower—it reflects the biological reality that obesity is a chronic condition requiring ongoing management. Semaglutide addresses the hormonal and neurological drivers of appetite and metabolism that don't simply reset after weight loss. Continuing the 2.4mg dose maintains GLP-1 receptor activation, preserving appetite suppression and metabolic benefits achieved during the weight loss phase.

Our prescribers support patients in developing sustainable long-term treatment plans. Some may eventually trial dose reduction to 1.7mg or 1mg if weight stability is maintained, though this requires careful monitoring. Others remain on 2.4mg indefinitely as part of a comprehensive weight management strategy. At £124.99 per month from Cured Pharmacy, long-term Wegovy treatment represents a cost-effective investment in sustained health outcomes, particularly when compared to the medical costs associated with obesity-related comorbidities.

Can You Switch Between Wegovy Doses?

Dose adjustments should only occur under prescriber guidance. If you experience intolerable side effects at a higher dose, your prescriber may recommend returning to the previous dose level temporarily. Conversely, if weight loss plateaus at a sub-therapeutic dose, escalation to the next level may be appropriate. Never adjust your Wegovy dose independently—all changes require clinical assessment to ensure safety and efficacy.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Novo Nordisk. (2023). Wegovy (semaglutide) injection 2.4 mg: Prescribing Information. Novo Nordisk A/S. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., ... & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.